digi.bio

Digi.Bio is an early-stage biotech tools company founded in 2019, leveraging a proprietary combination of digital microfluidics, high-content imaging, and AI/ML analytics to provide unprecedented single-cell functional analysis for drug discovery and development. The company's core value proposition is enabling real-time, dynamic tracking of cell behaviors—like serial killing by CAR-T cells—to deconvolute therapy heterogeneity and identify best-performing candidates. Operating as a platform and services provider, Digi.Bio aims to reduce the time and cost of bringing cell-based and immunotherapies to market by offering deeper, data-rich insights than conventional bulk assays. The company is privately held, likely pre-revenue, and based in Amsterdam.

Integrated single-cell analysis platform combining digital microfluidics (EWOD lab-on-a-chip), high-content live-cell imaging, and AI/ML analytics to track cell motility, interactions, and cytotoxic function over time.

Competition includes large life science tool providers (e.g., Sartorius, Revvity) with high-content screening systems and specialized startups in single-cell functional analysis. Digi.Bio's key differentiator is the integrated, dynamic tracking of cell-cell interactions and serial killing within an automated microfluidic environment.